In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Somapacitan | Natural peptide HGH (somatotropin) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 320 | 1,108 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 83 (83 in people) | 110 (108 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 · 8 active | 358 · 32 active72 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Sogroya says: “Replacement of endogenous GH in adults with GHD”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Somapacitan | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 78744 | 1069115 |
| Linear growth |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
2020 |
1301264 |
| Adverse eventsWhole body | 7575 | 60582 |
|---|
| Bone and jointMusculoskeletal | 22 | 12611511 |
|---|
| Body compositionMetabolic and weight | 55 | 109109 |
|---|
| Glycemic controlMetabolic and weight | 2525 | 8585 |
|---|
| LipidsMetabolic and weight | 44 | 7373 |
|---|
| Body weightMusculoskeletal | 14122 | 46415 |
|---|
| Exercise and physical functionWhole body | 33 | 4141 |
|---|
| PharmacokineticsPharmacology | 382216 | 23320 |
|---|
| Receptor activity and mechanismPharmacology | 918 | 2626 |
|---|
| Quality of lifeWhole body | 33 | 2121 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Somapacitan differs from Human growth hormone at 1 position.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Somapacitan | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | 11.2 cm/year Height velocity Dose studied: 0.16 mg/kg/week52 weeksn = 2002022 | 9.78 cm/year Height velocity · somatropin at month 12 Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022 |
11.2 cm/year
Height velocity
Dose studied: 0.16 mg/kg/week52 weeksn = 2002022
9.78 cm/year
Height velocity · somatropin at month 12
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Somapacitan | HGH (somatotropin) |
|---|---|---|
| Treatment adherence and retentionWhole bodyCompared as: value in the arm that got the peptide, in % | 95.8% Mean adherence Dose studied: 0.16 mg/kg/week52 weeksn = 2002022 |
No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Linear growthEndocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | 9 cm/year Height velocity Dose studied: 0.24 mg/kg/week52 weeksn = 1052026 | No comparable result 42 randomized-trial results measure it in another way or another unit. |
|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in gr/cm2 | −0.036 gr/cm2 Estimated difference 24 weeksn = 292025 | No comparable result 29 randomized-trial results measure it in another way or another unit. |
|---|
| Quality of lifeWhole bodyCompared as: value in the arm that got the peptide, in score points | −9.34 score points Estimated treatment difference in change from baseline · somapacitan 0.16 mg/kg/wk minus daily GH at week 52 Dose studied: 0.16 mg/kg/wk52 weeksn = 282020 | No comparable result 4 randomized-trial results measure it in another way or another unit. |
|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in cm² | −1.74 cm² Estimated treatment difference · somapacitan minus daily GH at week 52 52 weeksn not reported2020 | No comparable result 14 randomized-trial results measure it in another way or another unit. |
|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in per 100 patient-years | 312.7 per 100 patient-years Adverse event rate 52 weeksn = 622020 | No comparable result 16 randomized-trial results measure it in another way or another unit. |
|---|
95.8%
Mean adherence
Dose studied: 0.16 mg/kg/week52 weeksn = 2002022
No comparable result
2 randomized-trial results measure it in another way or another unit.
9 cm/year
Height velocity
Dose studied: 0.24 mg/kg/week52 weeksn = 1052026
No comparable result
42 randomized-trial results measure it in another way or another unit.
−0.036 gr/cm2
Estimated difference
24 weeksn = 292025
No comparable result
29 randomized-trial results measure it in another way or another unit.
−9.34 score points
Estimated treatment difference in change from baseline · somapacitan 0.16 mg/kg/wk minus daily GH at week 52
Dose studied: 0.16 mg/kg/wk52 weeksn = 282020
No comparable result
4 randomized-trial results measure it in another way or another unit.
−1.74 cm²
Estimated treatment difference · somapacitan minus daily GH at week 52
52 weeksn not reported2020
No comparable result
14 randomized-trial results measure it in another way or another unit.
312.7 per 100 patient-years
Adverse event rate
52 weeksn = 622020
No comparable result
16 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S301 participants31 Oct 2014 to 7 May 2018
Growth Hormone Disorder · Adult Growth Hormone Deficiency
Novo Nordisk A/S200 participants20 May 2019 to 30 Sept 2025
Growth Hormone Deficiency in Children
Novo Nordisk A/S110 participants22 Jul 2021 to 18 Dec 2023
Growth Hormone Deficiency in Children
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.